UPDATE: Morgan Stanley Reiterates Equal-Weight Rating, Removes PT on Pharmacyclics Following VA Contract News


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


In a report published Thursday, Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Pharmacyclics (NASDAQ: PCYC), but removed the $101.00 price target.In the report, Morgan Stanley noted, “This morning the Veterans Affairs National Acquisition Center posted a contract on fbo.gov which indicated it could acquire Imbruvica at a fixed price for five years with four one year extensions. The estimated total contract value published was $3.8B. Since this morning the contract (VA797P14R0033) has been removed from the website; we are unsure why it was removed.”Pharmacyclics closed on Wednesday at $127.81.
Posted In: Analyst ColorPrice TargetAnalyst RatingsMatthew HarrisonMorgan Stanley